Research-use-only context. This article summarizes peer-reviewed in vitro and pre-clinical research findings on BPC-157 at the molecular level. It is not a dosing guide, not medical advice, and not a recommendation for use in humans or animals. American Peptides supplies BPC-157 strictly for in vitro laboratory research.
If you've spent any time in the BPC-157 literature, you've noticed the same four signaling pathways come up in study after study. Below is a clean reference summary of each — what the research has shown, what the open questions are, and where the citations live.
This is the technical reference we wish existed when we were building our COA review process. It's written for working researchers, not for marketing.
What BPC-157 actually is
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide originally identified as a partial sequence of human gastric juice protein. The published amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (1).
Its molecular weight is approximately 1,419.5 Da. It is reported to be stable in acidic conditions for extended periods — a feature that has made it the subject of significant orogastric research interest in animal models.
Most BPC-157 published research originates from a single research consortium led by Predrag Sikiric at the University of Zagreb, with parallel work from groups in China, Croatia, and the United States.
The four pathways most studied
1. Nitric oxide (NO) system
Multiple animal-model studies report BPC-157 modulates the L-arginine-NO pathway (2,3). Researchers have shown the peptide appears to counteract both pro-NO (e.g., L-arginine excess) and anti-NO (e.g., L-NAME) interventions, suggesting a regulatory rather than directional effect on NO synthesis.
Open question in the literature: Whether BPC-157's NO-modulating activity is direct (binding endothelial nitric oxide synthase) or indirect (via upstream receptor activation). No direct binding affinity has been published as of this writing.
2. Growth hormone receptor (GHR) expression
A 2017 Chang et al. paper in Journal of Applied Physiology reported BPC-157 increases GHR expression in tendon fibroblast cell cultures (4). This is the most-cited mechanism candidate in the tendon-research literature.
The proposed sequence: BPC-157 → upregulated GHR → enhanced response to GH in the culture medium → increased fibroblast proliferation and collagen synthesis in vitro.
Open question: Whether this effect persists in vivo at non-supraphysiological levels of circulating GH. The cell-culture environment in published work uses GH supplementation that may not reflect baseline physiological conditions.
3. Transforming growth factor-beta (TGF-β)
Several rat-model studies of muscle and tendon injury report increased TGF-β expression in BPC-157-treated tissue compared to controls (5,6). TGF-β is a master regulator of fibroblast activity, extracellular matrix deposition, and inflammatory resolution.
This is the pathway most frequently invoked to explain the "body protection compound" name — TGF-β orchestrates much of what is studied under the label of tissue remodeling in animal models.
4. VEGF and angiogenesis
Vascular endothelial growth factor (VEGF) signaling appears in ulcer-research and ischemic-injury research (7). The findings suggest BPC-157 is associated with revascularization through enhanced VEGF expression at injury sites in animal models — though again, the mechanism (direct or indirect) remains unestablished.
Of the four pathways, VEGF research has the strongest in vivo signal but the weakest mechanistic clarity.
What's NOT yet established
For a peptide with this much research interest, several fundamentals are still missing from the published record:
- No published high-affinity receptor binding partner. BPC-157 has no known canonical receptor as of this writing.
- No published human pharmacokinetic data. Half-life, bioavailability, and metabolism in humans are not in the literature.
- No FDA-approved indication. BPC-157 is not approved for any therapeutic use in humans by any major regulatory agency.
Researchers planning protocols should treat BPC-157 as exactly what it is: a pre-clinical research compound with signals across multiple pathways but no established mechanism of action.
Why the COA matters more than usual
When a peptide's mechanism is this incompletely characterized, the variable that matters most for reproducible research is purity. Impurities at the 0.5–2% level can be biologically active in unrelated pathways, confounding any signal in your study.
Every BPC-157 lot we ship to research customers has an independent third-party HPLC and mass spec analysis and is shipped only when purity ≥ 99.0%. The batch-specific COA is linked on the BPC-157 product page.
This is the practical reason "research-grade" matters: when the underlying biology has open questions, you don't want material-quality questions stacked on top.
Frequently Asked Questions
Does BPC-157 have a known receptor?
As of this writing, no high-affinity canonical receptor for BPC-157 has been published. Most proposed mechanisms are downstream pathway observations (NO, GHR, TGF-β, VEGF) rather than a defined binding partner.
Why does purity matter so much for BPC-157 research?
Because the mechanism is incompletely characterized, any confounding biological activity from a 0.5–2% impurity can be mistaken for a real signal. Batch-specific HPLC and mass spec verification reduces that risk.
Is BPC-157 a stable peptide in aqueous solution?
BPC-157 is described in the literature as a relatively stable pentadecapeptide, including under acidic conditions, which is why it is often referred to as a stable gastric peptide. In a research setting, reconstituted solutions are still kept refrigerated and protected from light, because peptide stability data are concentration- and buffer-dependent and should be verified per lot.
What pathways are most often cited in BPC-157 mechanism studies?
Published model-system work most frequently references the nitric oxide (L-arginine/NO) system, vascular signaling involving VEGF, growth-hormone-receptor expression, and TGF-beta-associated pathways. These are downstream observations in experimental models, not a defined high-affinity receptor, so they are best understood as mechanistic hypotheses rather than established binding interactions.
Citations
- Sikiric P. et al. "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract." Curr Pharm Des. 2011;17(16):1612-32.
- Sikiric P. et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Curr Neuropharmacol. 2016;14(8):857-865.
- Boban-Blagaic A. et al. "The influence of the L-arginine-NO system on the BPC 157 effect on noradrenaline-induced hypertension." Eur J Pharmacol. 2007;574(2-3):170-9.
- Chang C.H. et al. "BPC-157 Increases Growth Hormone Receptor Expression in Tendon Fibroblasts." J Appl Physiol. 2017;122(6):1495-1503.
- Mikus D. et al. "Pentadecapeptide BPC 157 cream improves burn-wound healing in rats." Burns. 2001;27(8):817-27.
- Sikiric P. et al. "Diclofenac-induced gastric, intestinal and liver lesions in mice: pentadecapeptide BPC 157 counteracts." J Physiol Pharmacol. 2017;68(5):747-55.
- Hsieh M.J. et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and signaling." J Mol Med (Berl). 2017;95(3):323-333.
This article is for laboratory research reference only. American Peptides products are sold strictly for in vitro research. Not for human consumption.
Compliance Notice: American Peptides products are sold strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institutions safety protocols and applicable laws.
